JP Morgan Chase’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
Other funds holding FOLD
VCM
PCM
VPM
GCL
JP Morgan Chase's FOLD Position: Q1 2026 in Review
JP Morgan Chase increased its Amicus Therapeutics (FOLD) stake by 82% in Q1 2026, buying an estimated $43.5M and bringing the position to 6,749,190 shares worth $97.4M. The position accounts for 0.01% of the portfolio, ranked #998.
JP Morgan Chase first reported a position in FOLD in Q2 2013 and has held it in 45 quarters since. The position peaked at $253M in Q4 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- JP Morgan Chase held 6,749,190 shares of Amicus Therapeutics worth $97.4M as of Q1 2026.
- JP Morgan Chase bought 3,031,827 Amicus Therapeutics shares in Q1 2026, an estimated $43.5M.
- Amicus Therapeutics made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #998 holding.
- JP Morgan Chase first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 45 quarters since.
- JP Morgan Chase's Amicus Therapeutics position peaked at $253M in Q4 2023.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.